FierceBiotech 2025年12月9日 ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap
FierceBiotech 2025年12月8日 With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec
FierceBiotech 2025年12月8日 Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets
FierceBiotech 2025年12月8日 AbbVie hands back phase 1 duties for chronic inflammation drug to partner OSE
FierceBiotech 2025年12月7日 ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch
FierceBiotech 2025年12月7日 ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success
FierceBiotech 2025年12月6日 ‘Market’s thinking is backwards’: FDA’s 1-trial approval plan would boost R&D spend, Jefferies says
FierceBiotech 2025年12月5日 Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data
FierceBiotech 2025年12月5日 'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out
FierceBiotech 2025年12月5日 How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle